Bleeding Risk With Apixaban Versus Rivaroxaban: A Reference Trial Emulation Predicting the Results of COBRRA-VTE and COBRRA-AF Using US Health Care Claims. [PDF]
Circ Popul Health OutcomesMahesri M +6 more
europepmc +1 more source
Anticoagulation in Advanced Chronic Kidney Disease: Navigating Uncertainty. [PDF]
Turk J HaematolVelioğlu A.
europepmc +1 more source
Updates in Hospital Medicine: Anticoagulation. [PDF]
J Brown Hosp MedTsomides AM, Zemrak WR, Gordon LB.
europepmc +1 more source
Coronary Embolism: A Rare Complication After Takotsubo Cardiomyopathy. [PDF]
CureusMao B +5 more
europepmc +1 more source
A review of the pharmacokinetics, pharmacodynamics, efficacy, and safety of direct oral anticoagulants in patients undergoing bariatric surgery. [PDF]
Res Pract Thromb HaemostKröll D, Stirnimann G, Wentworth D.
europepmc +1 more source
Oral anticoagulation and left atrial appendage closure in dialysis atrial fibrillation: between stroke prevention and bleeding hazard. [PDF]
Clin Kidney JGenovesi S, Kuno T, Floege J, Zoccali C.
europepmc +1 more source
Real-world bleeding risk and molecular interaction profiles of direct oral anticoagulants: a comparative study integrating clinical outcomes and <i>in silico</i> docking. [PDF]
Front PharmacolOnar LC, Guner E, Yilmaz I.
europepmc +1 more source
Prevalence of Potentially Inappropriate Apixaban Prescribing Within a Single-Centre Tertiary Hospital. [PDF]
Australas J AgeingCreeper KJ +5 more
europepmc +1 more source
Rational Design of Novel Isosteviol-Derived Factor Xa Inhibitors Using Integrated QSAR, Molecular Docking, Molecular Dynamics, and MM/GBSA Analyses. [PDF]
Biology (Basel)Gordon P +4 more
europepmc +1 more source
Red cell exchange removes apixaban in patients with sickle cell disease. [PDF]
TransfusionBoyle K +6 more
europepmc +1 more source